Ventfort
Research OnlyA cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for vascular health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Vascular cytamin · Blood vessel peptides · A-3 vascular peptides
Preclinical evidence only
- Preclinical
- 83%
- Human research
- 0%
Based on 6 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Mechanism of Action
Ventfort is a cytamin-class supplement containing peptide complexes derived from blood vessel tissue.
Proposed Mechanisms
- Endothelial Support - Claimed to support blood vessel lining function
- Vascular Tone - Proposed effects on vessel elasticity
- Cardiovascular Health - Marketed for overall vascular support
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials
- NOT a treatment for cardiovascular disease
- Not approved by any Western regulatory agency
Vesugen
CompatibleBoth target vascular function - Vesugen is synthetic KED tripeptide, Ventfort is tissue-derived cytamin supplement.
Cardiogen
CompatibleBoth target cardiovascular system - Cardiogen for heart, Ventfort for blood vessels.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ventfort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-14 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01
EVX-01 is an investigational, patient-specific neoantigen peptide vaccine studied with anti-PD-1 therapy in advanced melanoma. Two small single-arm cohorts show vaccine-specific T-cell responses and observed tumor responses, but they cannot establish how much EVX-01 adds to checkpoint treatment.